A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Nektar Therapeutics
Eli Lilly and Company
Georgetown University
Centro Nacional de Investigaciones Oncologicas CARLOS III
Eli Lilly and Company